Tackling barriers to weight-related medications is often more about communication, documentation, insurance, and logistics than it is about your body
An association of treatment with GLP-1RA receptor agonists and DR was originally reported in the SUSTAIN-6 trial, which demonstrated a statistically significant increase in risk of new or worsening DR, with 3% incidence in the semaglutide group versus 1.8% in the placebo group (hazard ratio, 1.76
Headache at higher per-injection doses community sources describe dose-splitting or reducing to resolve
Similarly, coaching tools that provide personalized, daily recommendations on food choices and lifestyle to augment the support of 1:1 coaching present a scalable, impactful opportunity
This multifaceted approach makes it an effective option for both glycemic control and weight loss